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ABSTRACT
Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, 
and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with 
diffuse large B-cell lymphoma (DLBCL) compared with CHOP. The mechanism of 
rituximab-induced cell death is poorly understood. We found that rituximab does not 
enhance the directly killing efficacy of CHOP, as tested on a panel of DLBCL cell lines. 
Rituximab induced a rapid release of HMGB1 (High mobility group protein B 1). This 
release is independent of cell death but significantly correlated with an inhibition on 
STAT3 activity. In the resting state, HMGB1 co-localizes and interacts with STAT3 
in the nucleus of DLBCL cells. Treatment with rituximab breaks this binding and 
triggers HMGB1 release. Treatment with R-CHOP but not CHOP significantly increased 
plasma HMGB1 and decreased IL-10 concentrations in DLBCL patients compared with 
controls. The conditioned medium from rituximab-treated DLBCL cells is able to trigger 
dendritic cell maturation, phagocytosis, and IFN-γ secretion by cytotoxic T cells. In 
conclusion, our results demonstrate that rituximab induces an inhibition on STAT3 
activity, leading to increased HMGB1 release and decreased IL-10 secretion, which 
elicits immune responses, suggesting that indirect effects on the immune system 
rather than direct killing contribute to elimination of DLBCL.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) and 
follicular lymphoma (FL) are the most common forms 
of aggressive and indolent non-Hodgkin lymphomas 
(NHLs), respectively. The first-line therapy for DLBCL 
and FL is rituximab, a monoclonal anti-CD20 antibody, 
plus cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) [1, 2]. Treatment with R-CHOP 
achieved high response rates and led to significant 
improvements on overall survival rates in patients with 
NHLs compared with those treated with CHOP alone 
[3–6]. In some of B-cell malignancies, rituximab alone 
can induce high overall response rates and long term 
remissions [7, 8]. Despite its undeniable value as a 
component of therapy for anti-B cell malignancies, the 
mechanisms of action responsible for rituximab’s anti-
tumor effects are not fully understood [9].
Over the last decade, the cell killing modalities 
of anti-CD20 antibodies on malignant B-cells were 
considered as complement-dependent cytotoxicity, 
antibody-dependent cellular cytotoxicity, apoptosis, 
inhibition of STAT3 activity, and lysosome permeability-
mediated cell death [3, 9–12]. However, in vitro studies 
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showed that rituximab is the weakest killer on malignant 
B-cells among anti-CD20 antibodies [10, 13, 14]. The 
cell-killing modality of rituximab is still elusive. So far, 
there is little convincing evidence to show that the anti-
tumor effect of rituximab is mediated by direct killing to 
malignant B-cells. Previous reports showed that the anti-
CD20 antibody-treated lymphoma cells are taken up and 
processed by antigen presenting dendritic cells (DCs) with 
subsequent cross-presentation of tumor-derived antigens 
to T cells [15–17]. This suggests that anti-CD20 antibodies 
may have a ‘vaccinal effect’ and exert therapeutic effects 
through the induction of an adaptive cellular immune 
response. However, the precise mechanism by which the 
anti-CD20 antibody induces immune responses is also 
unclear.
In recent years a new concept ‘immunogenic 
cell death’ (ICD), a cell death modality that stimulates 
immune response against dead cell antigens, has drawn 
great attention in the field of anticancer therapy. The 
immunogenic characteristics of ICD are mainly mediated 
by damage-associated molecular patterns (DAMPs), which 
include pre-mortem surface exposed calreticulin (CRT), 
secreted ATP, and post-mortem released high mobility 
group protein B1 (HMGB1) after the exposure to certain 
cytotoxic agents. These danger signals are recognized 
by antigen-presenting cells such as DCs followed by the 
formation of T cell-mediated adaptive immunity [18–22].
HMGB1 is a non-histone chromatin protein and 
universally expressed by all nucleated cells. It can be 
actively secreted by cells of the innate immune system in 
response to pathogenic products and passively released 
by injured cells as they succumb to primary or secondary 
necrosis [23–25]. Extracellular HMGB1 has emerged as 
a key mediator in the regulation of immune responses to 
infection and sterile injury [26]. The release of HMGB1 
by dying cancer cells is mandatory to license host DCs to 
process and present tumor antigens. Extracellular HMGB1 
interacts with Toll-like receptors (TLRs) and receptor for 
advanced glycation end products (RAGE) on the DCs, 
which are involved selectively in the cross-priming of 
anti-tumor T lymphocytes in vivo [27, 28]. It has been 
reported that the type II anti-CD20 antibody GA101 
induces both programmed cell death and HMGB1 release 
from Raji lymphoma cell line. The conditioned medium 
from GA101-treated cells elicits maturation of DCs [29]. 
However, Rituximab showed less cytotoxic effect on Raji 
cells.
On the basis that rituximab induces immune 
response in vivo, we hypothesized that treatment with 
rituximab might elicit ICD in malignant B-cells. To test 
this postulate, we compared cell death modalities between 
CHOP and R-CHOP-treated DLBCL cells and determined 
rituximab-induced HMGB1 release from DLBCL cells 
in vitro and in vivo. We found that rituximab-induced 
HMGB1 release from a panel of DLBCL cell lines is 
associated with inhibition of STAT3 activity.
RESULTS
Rituximab does not enhance CHOP-induced cell 
death in DLBCL cells
Firstly, we compared the killing efficacies of 
R-CHOP and CHOP on malignant B-cells in vitro. Four 
DLBCL cell lines, Su-6, Su-8, Su-10, and DoHH2, were 
treated with 3 different doses of CHOP and/or 10 μg/ml 
of rituximab for 24 hours. Treatment with 20 μg/ml of 
CHOP induced a significantly increased PARP cleavage, 
a marker for apoptosis. However, there was no significant 
difference in the amount of PARP cleavage between 
CHOP and R-CHOP-treated cells (Figure 1A and 1B, 
Supplemental Figure 1A). The four cell lines showed 
differential sensitivities to CHOP or R-CHOP-induced 
cell death and cytotoxicity (Figure 1C–1F), but again there 
was no statistical difference between the treatment with 
CHOP and R-CHOP, as analyzed by ANOVA (P > 0.05). 
GA-101, another anti-CD20 antibody, significantly 
induced cytotoxicity on DLBCL cells but rituximab failed 
to do so (Figure 1G). These results demonstrate that 
rituximab may not kill DLBCL cells directly.
Treatment with rituximab induces a rapid 
HMGB1 release from DLBCL cells
Using Western blotting, we detected that R-CHOP 
but not CHOP induced a significantly increased 
HMGB1 release from DLBCL cells after treatment 
for 4 hours, without inducing changes in the levels of 
HMGB1 expression in these cell lines. CHOP neither 
induced nor enhanced rituximab-mediated HMGB1 
release (Figure 2A–C and Supplemental Figure 1B). 
We monitored rituximab-induced HMGB1 intracellular 
shuttling using fluorescent microscopy. In untreated 
DLBCL cells, HMGB1 mainly localizes in the nucleus, 
although a weak expression of cytoplasmic HMGB1 
can be detected. After treatment with rituximab alone 
for 4 hours, a strong staining of HMGB1 appeared in 
the cytoplasm (Figure 2D). Using Western blotting, we 
confirmed that both GA-101 (type-II anti-CD20 antibody) 
and rituximab induced HMGB1 release from DLBCL 
cells after treatment for 4 hours. An anti-CD3 antibody, 
OKT3 could not induce HMGB1 release on DLBCL cells 
(Figure 2E and 2F), indicating that induction of HMGB1 
release is not a function of generic antibodies.
It was reported that HMGB1 release from 
monocytes is associated with lysosome exocytosis [30]. 
Coincidently, other study found that anti-CD20 antibodies 
induce lysosomal permeability in malignant B-cells 
[10, 14]. We therefore tested whether rituximab-induced 
the release of HMGB1 and cathepsin D, a lysosomal 
enzyme, follow the same pattern. Results from fluorescent 
microscopy and colocalization analysis showed that 
HMGB1 and cathepsin D shared colocalization in 
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Figure 1: Comparison of CHOP and R-CHOP-induced killing in DLBCL cell lines. DLBCL cell lines were treated with 5, 10, 
or 20 μg/ml of CHOP, 10 μg/ml of rituximab, or R-CHOP for 24 hours. A. PARP cleavage. A group of representative Western blots of PARP 
cleavage induced by CHOP or R-CHOP. ‘PARP’ means full length PARP (MW = 116) and ‘C-PARP’ indicates cleaved PARP (MW = 86). 
β-tubulin was used as a loading control. B. Statistical analysis of PARP cleavage. Ratios of cleaved PARP to PARP were analyzed by 
densitometry. Data shown were mean ± SD from 4 different cell lines. ‘*’ means significantly increased PARP cleavage in 20 μg/ml CHOP-
treated groups compared with their controls. C and D. CHOP (C) or R-CHOP (D) induced cell death. Cells were stained with 7-AAD and 
7-AAD positive cells were determined by flow cytometry as dead cells. E and F. CHOP (E) or R-CHOP (F) –mediated cytotoxicity. After 
treatment with CHOP or R-CHOP for 48 hours, decreased viability (cytotoxicity) was determined by CCK-8 assay. G. Rituximab or GA-
101-induced cytotoxicity. Cells were treated with 10 μg/ml rituximab (Ritux) or GA-101 for 48 hours and the cytotoxicity was determined 
by CCK-8 assay. Significantly increased cytotoxicity in GA-101-treated group was analyzed using means from 4 different cell lines. (C–F) 
Data shown were mean ± SD from 3 independent experiments.
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Figure 2: Rituximab induced HMGB1 release. A-C. Four DLBCL cell lines in 2 × 106/ml were treated with rituximab for 4 hours. 
HMGB1 in the conditioned medium (50 μl) and cytosolic extracts were determined by Western blotting using a mouse anti-HMGB1 antibody. 
BSA and β-tubulin were used as loading controls for the conditioned medium and the cytosolic proteins, respectively. (A) A group of representative 
Western blots; (B and C) Statistical analysis of HMGB1 protein levels in the conditioned medium (B) and cytosolic extracts (C) Data shown 
were mean ± SD from 4 DLBCL cell lines. ‘***’ in (B) indicates significant difference of HMGB1 levels in the conditioned medium between 
R-CHOP and CHOP treated samples. D. HMGB1 translocation. Cells were treated with rituximab alone for 4 hours. Fixed/Permeabilized cells 
were co-stained with HMGB1 antibody showing red and DAPI (blue) for nuclear localization. E. GA-101 antibody-induced HMGB1 release. 
Cells were incubated with or without 10 μg/ml GA-101 antibody for 4 hours. HMGB1 in the conditioned medium was determined by Western 
blotting. F. Anti-T cell antibody does not induce HMGB1 release in malignant B-cells. Su-6 and Su-8 cell lines were treated with 10 μg/ml anti-
CD3 (OKT3) antibody for 4 hours. Rituximab (R)-treated cells were used as a positive control. (G and H) Comparison of the patterns between 
HMGB1 and cathepsin D release. G. DoHH2 cells were treated with rituximab for 4 hours. Fixed/Permeabilized cells were co-stained with 
anti-HMGB1 (red) and anti-cathepsin D (green) antibodies, and DAPI (blue). Arrow shows the colocalization of HMGB1 and cathepsin D. The 
single color images were shown in the Supplemental Figure 2A. H. Colocalization analysis. PDM images and correlation coefficient (Rr) were 
generated by the intensive correlation analysis using ImageJ software. The orange color and higher Rr indicate a colocalization and the blue color 
and a lower or negative Rr means a segregation.
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untreated DLBCL cells, as shown the yellow dots in 
Figure 2G and Supplmental Figure 2A and orange pixels 
(pseudo-colored) in Figure 2H. However, the Rr values 
decreased from 0.874 to 0.406 after treatment with rituximab 
(Figure 2H), indicating a decreased colocalization. We further 
co-stained cathepsin D or HMGB1 with cytoplasmic 
S6 ribosomal protein. Rituximab-induced cathepsin D 
release from the lysosome was restricted inside the cell 
(Supplemental Figure 2B) but HMGB1 was released to the 
outside (Supplemental Figure 2C). Using Western blotting, 
we confirmed that treatment with rituximab alone induced 
a release of HMGB1 but not cathepsin D (Supplemental 
Figure 2D). Taken together, our results demonstrate for 
the first time that rituximab induces HMGB1 release from 
live malignant B-cells and this release is unlikely via the 
mechanism of lysosomal exocytosis.
Rituximab-induced HMGB1 release and STAT3 
inhibition are coupled events
The function of HMGB1 in the nucleus is to help 
transcription factors and other nuclear proteins bind to 
their cognate sites by bending the DNA molecule [31]. 
One of the cytotoxic functions of rituximab is to inhibit 
the activity of transcription factor STAT3 [12]. However, 
the functional link between STAT3 and HMGB1 is 
unknown. We therefore tested whether rituximab-induced 
HMGB1 release is associated with the inhibition of 
STAT3. DLBCL cells were treated with rituximab and/or 
IL-10, a stimulator for STAT3, and then co-stained with 
HMGB1 (red) and either STAT3-PS727 or STAT3-PY705 
(green) antibodies (Figure 3A and 3B and Supplemental 
Figure 3). In control cells, most STAT3 and HMGB1 were 
localized in the nucleus, although weakly expressed in 
the cytoplasm. Treatment with IL-10 stabilized nuclear 
localization of both STAT3 and HMGB1. Rituximab 
induced a shuttling of both STAT3/HMGB1 to the 
cytoplasm and HMGB1 release, even in the presence of 
IL-10. Using colocalization analysis, it was shown that 
IL-10 enhanced but rituximab decreased STAT3 and 
HMGB1 nuclear colocalization (Figure 3C).
The correlation between STAT3 activity and 
HMGB1 release were quantitatively analyzed by 
Western blotting in four DLBCL cell lines. First, we 
found that rituximab significantly inhibited STAT3 
activity in a time-dependent manor (Figure 4A and 4B 
and Supplemental Figure 4A) and it also significantly 
inhibited IL-10-mediated STAT3 activation (Figure 4C–E  
and Supplemental Figure 4B). Unsurprisingly, 
IL-10 inhibited HMGB1 release from both control 
and rituximab-treated cells (Figure 4F and 4G). The 
association between STAT3 activity and HMGB1 release 
were analyzed using Pearson’s correlation method 
in combination of data from Figure 4D, 4E and 4G. 
Statistical data (Supplemental Figure 5A and 5B) showed 
that the activities of both STAT3-PS727 and STAT3-PY705 
were significantly and negatively correlated with levels of 
extracellular HMGB1 (P < 0.01; γ = −0.88 and −0.89).
To further confirm the association between STAT3 
and HMGB1, we conducted co-IP to determine the binding 
between two proteins using either anti-HMGB1 or anti-
STAT3-PY705 antibody. There was a weak binding between 
STAT3 and HMGB1 in the control cells. The levels of 
binding were increased or decreased upon treatment with 
either IL-10 or rituximab (Figure 5A), demonstrating 
that rituximab reduced the binding between two proteins. 
Importantly, AG490, an inhibitor of JAK2/STAT3, 
induced HMGB1 release in a dose and time-dependent 
manor (Figure 5B). AG490-induced HMGB1 release can 
be inhibited by IL-10 (Figure 5C). Taken together, these 
results demonstrate that inhibition of STAT3 by rituximab 
breaks the binding between STAT3 and HMGB1. This 
could be the cause of HMGB1 release.
Plasma from R-CHOP-treated patients  
show significantly increased HMGB1  
and decreased IL-10
Using ELISA kits, we quantitatively confirmed 
that rituximab induced a significantly increased HMGB1 
release and a significantly decreased IL-10 secretion in 
DLBCL cell lines (Figure 6A and 6B). To determine 
whether treatment with rituximab induces HMGB1 
release and STAT3 inhibition in vivo, we compared 
HMGB1 and IL-10 concentrations in the plasma of 
DLBCL patients before and after treatment with CHOP 
(n = 24) and R-CHOP (n = 16). The median levels of 
HMGB1 and IL-10 in DLBCL patients plasma were 
17.88 ng/ml and 9.49 pg/ml, respectively, and were 
higher than previously published normal levels of 
HMGB1 <10 ng/ml [32] and IL-10 <3 pg/ml [33]. After 
treatment with R-CHOP, HMGB1 levels in the plasma 
were significantly increased (Figure 6C) and IL-10 levels 
were significantly decreased (Figure 6E) compared with 
their untreated samples. However, treatment with CHOP 
did not affect the plasma levels of HMGB1 and IL-10 
(Figure 6D and 6F). These results further confirmed that 
treatment with rituximab induces STAT3 inhibition and 
HMGB1 release from DLBCL B-cells.
Treatment with rituximab elicits an immune 
response
Extracellular HMGB1 is one of the ICD markers. 
We tested whether treatment with rituximab elicits other 
ICD markers, such as CRT exposure and ATP release. 
Treatment with CHOP or rituximab alone increased 
phosphorylation of eIF2α (P-eIF2α), one of the precursors 
of CRT exposure (Supplemental Figure 6A). However, 
rituximab induced an overexpression of CRT protein 
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Figure 3: Rituximab induced intracellular shuttling of STAT3 and HMGB1. DoHH2 cells were treated with rituximab for 
4 hours. Cells were co-stained with a mouse anti-HMGB1 (red) and a rabbit anti-STAT3-PS727 A. or STAT3-PY705 B. antibodies (green). 
The arrow head shows the active STAT3 shuttled to the cytoplasm and the arrow indicates HMGB1 release from the cell. The single color 
images were shown in the Supplemental Figure 3. C. Colocalization analysis. PDM images and correlation coefficient (Rr) were generated 
by the intensive correlation analysis using WCIF ImageJ software. The orange color and higher Rr indicate a colocalization and the blue 
color and a lower or negative Rr means a segregation.
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Figure 4: Correlation between STAT3 inhibition and HMGB1 release. A and B. Rituximab-induced a time-dependent 
inhibition on STAT3 activity. (A) A group of representative Western blots and other groups of Western blots were presented in the 
Supplemental Figure 4A; (B) Statistical analysis of rituximab induced STAT3 inhibition. Data shown were mean ± SD of STAT3/β-tubulin 
from 4 different cell lines. Rituximab-induced significantly decreased STAT3 activities were compared with their controls using two-way 
ANOVA analysis. C, D and E. rituximab-induced STAT3 inhibition on IL-10 treated cells. DLBCL cells were treated with 10 ng/ml of IL10 
and/or 10 μg/ml of rituximab simultaneously. (C) A group of representative Western blots and other groups of Western blots were presented 
in the Supplemental Figure 4B; (D and E) Statistical analysis of rituximab-induced inhibition on STAT3-PS727 and (D) STAT3-PY705 (E) Data 
shown were mean ± SD from four different cell lines. Rituximab-induced significant inhibition of STAT3 activities on IL-10-treated cells 
were compared with those treated with IL-10 alone using two-way ANOVA analysis. F and G. Effects of IL-10 and rituximab on HMGB1 
release. After cells were treated with IL-10 and/or rituximab, the conditioned medium was used for Western blotting. (F) Western blotting 
detection of HMGB1 in the conditioned medium (M-HMGB1). BSA was used as a loading control. (G) Statistical analysis of IL-10 and/or 
rituximab on HMGB1 release. Data shown were mean ± SD of M-HMGB1/BSA from four DLBCL cell lines. IL-10 significantly inhibited 
HMGB1 release was compared with the control.
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Figure 5: Association between STAT3 and HMGB1. A. Protein binding between HMGB1 and STAT3-PY705. Su-6 and Su-8 
cell lines were treated with either IL-10 or HMGB1 for 4 hours. Proteins from cell extracts were precipitated with either a rabbit anti-
STAT3-PY705 or a rabbit anti-HMGB1 antibodies. Rabbit IgG was used as a negative control. After Co-IP, blots were probed with a mouse 
anti-HMGB1 or a mouse anti-STAT3-PY705 antibodies, respectively. B. AG490-induced time- and dose-dependent HMGB1 release. Cells 
were either treated with 25 μM AG490 up to 24 hours or with different doses of AG490 for 24 hours. HMGB1 in the conditioned medium 
was determined by Western blotting. Numbers under each blot are ratios of M-HMGB1/BSA. C. Roles of IL-10 and AG490 on STAT3 
activity and HMGB1 release. DLBCL cells were treated with IL-10 and or AG490 for 4 hours. Expression of STAT3-PY705 in the cell lysates 
and HMGB1 levels in the conditioned medium were determined by Western blotting.
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but did not induce CRT surface exposure on DLBCL 
cells (Supplemental Figure 6A and 6B). In addition, 
neither rituximab nor GA101 induced ATP secretion 
(Supplemental Figure 7).
We therefore tested whether HMGB1 in the 
conditioned medium from rituximab-treated cells could 
induce an immune response. Human immature dendritic 
cells (iDCs) (treated with GM-CSF and IL-4 for 5 days) 
were incubated with conditioned supernatants from 
rituximab treated cells for another 24 hours. Maturation 
of DCs was determined by expression of CD80 and CD83 
using flow cytometry. Rituximab-treated cell culture 
Figure 6: Quantitative analysis of HMGB1 and IL-10 levels. A and B. Rituximab induced HMGB1 release and inhibition on 
IL-10 production in DLBCL cell lines. Four DLBCL cell lines in 2 × 106/ml concentration were treated with rituximab for 4 hours. 10 μl of 
conditioned medium was used to measure concentrations of HMGB1 (A) and IL-10 (B) C and D. HMGB1 plasma concentrations before 
and after treatment with R-CHOP (C) or CHOP (D) E and F. IL-10 plasma concentrations before and after treatment with R-CHOP (E) or 
CHOP (F) Data shown are median ± interquartile range. Two pairs of extreme data, HMGB1 (from 135.38 to 25.67 ng/ml) and IL-10 (from 
432.45 to 458.97 pg/ml) before and after treatment with CHOP were removed from (D) and (F), respectively, for presentation purpose.
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Figure 7: Rituximab induced immune response in both DCs and cytotoxic T-cells. A. DC maturation. DCs were stimulated 
with conditioned supernatant of control or rituximab-treated cell culture medium. The maturation markers for DCs, CD83 or CD80, were 
evaluated by flow cytometry and compared between control and rituximab-treated groups. **P < 0.01. Data were expressed as mean ± SD 
and each value represented the mean of three replicates. B. Fluorescence microscopy analysis of phagocytosis. After 24 hours co-culture 
of immature DCs with rituximab-treated tumor cells, the engulfment of tumor cells was verified by fluorescence microscopy. DCs were 
stained with DiO (green) and Su-6 cells were stained with DiI (red). Double positive or yellow cells are fully phagocytized cells. C. IFN-γ 
production. Immature DCs were pulsed with rituximab-treated DLBCL cells for 24 hours and then co-cultured with autologous CD8+ T 
lymphocytes. IFN-γ concentration in the supernatant was assessed after 10 days using the IFN-γ ELISA kit.
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medium induced significantly increased expression of 
both CD80 and CD83, indicating maturation of DCs 
(Figure 7A). To determine phagocytosis, iDCs (treated 
with GM-CSF and IL-4 for 5 days) were co-cultured with 
DLBCL cells treated with saline, or rituximab for 24 hours 
and then, fluorescence microscopy was used to evaluate 
the phagocytosis of DCs. DCs activated with rituximab-
treated cells showed phagocytosis activity compared 
with the control, as shown by double positive, or yellow 
colored cells (Figure 7B). Moreover, the co-culture 
matured DCs with autologous CD8+ T cells significantly 
increased the secretion of IFN-γ by cytotoxic T-cells 
compared with the control (Figure 7C). These results 
demonstrate that conditioned supernatant from rituximab-
treated DLBCL cells can enhance immune response by 
inducing maturation and phagocytosis of DCs and up-
regulate cytotoxic function of T cells.
MATERIALS AND METHODS
Human DLBCL plasma
Plasma was collected from 40 DLBCL patients, 
(Supplemental Table 1) at diagnosis and after treatment 
with CHOP or R-CHOP for 2 weeks and stored at −80°C. 
DLBCL patients were diagnosed by standard criteria and 
treated in Tianjin Cancer Hospital, China during 2014. 
Ethical approval for this study was obtained from the 
ethics committee of Tianjin Medical University Cancer 
Institute and Hospital (Ethic number Ebc2014).
Cell lines and cell culture
Human DLBCL cell lines Su-DHL6 (Su-6), 
Su-DHL8 (Su-8), and Su-DHL10 (Su-10) were kindly 
provided by Professor Anthony Letai (Dana-Farber Cancer 
Institute) [34, 35] and the DoHH2 cell line was obtained 
from CRUK tissue bank [36]. Cell lines were routinely 
cultured in RPMI-1640 medium supplemented with 
10% heat-inactivated fetal calf serum (FCS) and 2.0 mM 
L-glutamine at 37°C in a 5%CO2 humidified incubator.
Treatment with CHOP or R-CHOP
The components of CHOP, cyclophosphamide, 
doxorubicin, vincristine and prednisolone were purchased 
from Sigma. Rituximab (MabThera) and GA101 were 
obtained from Roche. The stock solutions for CHOP were 
prepared individually and then mixed together according 
to the ratios of the in vivo treatment [6], as listed in 
Supplemental Table 2. Cells were treated with CHOP, or 
R-CHOP (CHOP plus 10 μg/ml of rituximab) for 24 or 
48 hours to induce cell death.
Cell death and cytotoxicity assays
To determine cell death, cells were stained with 
0.5 mg/ml of 7-AAD (KeyGen Biotech) for 10 min and 
7-AAD positive (dead) cells were determined by flow 
cytometry (BD FACS Canto II, BD, USA). CHOP or 
R-CHOP-induced cytotoxicity was assessed by Cell 
Counting Kit-8 (CCK-8, Beyotime Biotechnology) 
according to the manufacturer’s instruction. 
Briefly, 5000 cells in 100 μl were seeded in each well in 
a 96-well plate. After treatment with CHOP or R-CHOP 
for 48 hours, 10 μl of CCK-8 solution was added into 
each well and cells were further incubated for 1 hour. 
The OD values were determined by a plate reader at the 
wavelength of 450nm.
Western blotting analysis
Whole-cell extracts were prepared by lysing cells 
with the RIPA lysis buffer supplemented with protease 
inhibitor and phosphatase inhibitor cocktails (Sigma). 
Cellular protein lysates (20 μg) were separated by 
10% SDS-PAGE, and target proteins were detected 
by Western blotting, as described previously [37]. 
Antibodies were listed in Supplemental Table 3 and 4.
Determination of ICD markers
HMGB1 release was qualitatively and 
quantitatively determined by Western blotting and 
ELISA, respectively [32]. To determine CRT exposure, 
the cells were fixed with 0.25% of paraformaldehyde 
in PBS for 10 min and blocked with 3% bovine serum 
albumin (BSA). After stained with PE-conjugated 
anti-CRT antibody for 30 min, PE-positive cells were 
determined by flow cytometry. ATP concentration 
in the culture medium was performed using an ATP 
Determination Kit (Life technologies) according to the 
manufacturer’s instructions [37].
Preparation of human DCs and CD8+ 
T lymphocytes
Human peripheral blood mononuclear cells 
(PBMCs) were isolated from healthy donors by Ficoll-
Hypaque density gradient centrifugation and cultured in 
RPMI 1640 medium containing 10% FCS for 2 hours. 
DCs, which were generated from the adherent fraction 
of PBMCs [38], were cultured for 5 days in RPMI 1640 
medium containing 10% FCS, 20 ng/mL human GM-
CSF, and 10 ng/mL human IL-4 (Biolegend). Culture 
medium and cytokines were refreshed in every other day. 
On the day 5, the medium was replaced by rituximab-
treated conditioned medium or control medium and cell 
culture was continued for 24 hours. Autologous CD8+ 
T lymphocytes were magnetically isolated using CD8 
MicroBeads (Miltenyi Biotech, Germany) to obtain purity 
≥95% CD8+ T cells. The isolated T lymphocytes were 
cultured in RPMI 1640 medium containing 10% FCS and 
10 ng/mL human IL-2 (Biolegend) and the medium was 
replaced every other day [37].
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Immuno-staining and fluorescent microscopy
Cells on slides were fixed and permeabilized with 
Cytofix/Cytoperm reagents (BD) and blocked with a 
buffer consisting of 0.1% saponin and 5% serum (the type 
of serum corresponding to the isotype of the secondary 
antibody). Cells were co-stained with a monoclonal and 
a polyclonal primary antibody (Supplemental Table 3) for 
1 hour at room temperature. After washing with TBST 
(TBS containing 0.1% Tween-20), cells were incubated 
with Alexa-Fluor conjugated secondary antibodies 
(Supplemental Table 4) at 1:100 dilution. Slides were 
washed for 3 times with TBST, stained with 50 ng/ml 
DAPI (4′, 6-diamidino-2-phenylindole, Sigma), air-dried 
at 4°C in the dark, and mounted in ProLong® Gold anti-
fade reagent (Life Technologies) before being viewed 
under Nickon Intensilight C-HGFI fluorescent microscope 
(Nickon, Japan) [32].
The anti-tumor phagocytic function of matured 
DCs was assessed after DCs or DLBCL cells were 
labelled fluorescently with Vybrant™ DiO (V-22886) or 
DiI (V-22885) cell-labelling solutions (Life technologies), 
respectively. Briefly, DLBCL cells were treated with 
rituximab for 4 hours after stained with DiI (1:200 
dilution). DiO-loaded immature DCs (Day 5) were 
then incubated with the rituximab-treated cells. After 
co-culture for 24 hours, the cells were fixed with 4% 
paraformaldehyde for 20 min, washed in PBS for 20 min 
and mounted on slides and viewed under a fluorescent 
microscope. Double positive cells were considered as fully 
phagocytozed cells [37].
Colocalization analysis
Colocalization analysis was based on the theory that 
if two proteins are parts of the same complex, then their 
staining intensities should vary in synchrony, whereas if 
they are on different complexes or structures, they will 
exhibit asynchronous staining. The intensive correlation 
analysis (ICA) method was used for determine the levels 
of colocalization. Image of (PDM): the Product of the 
Differences from the Mean was used to qualitative 
analysis of colocalization. The levels of colocalization 
were quantitatively expressed by the Pearson’s correlation 
coefficient (Rr) using WCIF ImageJ software [39–41].
Co-immuno-precipitation (Co-IP)
Cell extracts were prepared with the RIPA buffer. 
200 μg Proteins were incubated at 4°C overnight 
with a rabbit anti-STAT3-PY705, a mouse anti-HMGB1 
antibody, or a control IgG. The immune complexes were 
immuno-precipitated on Protein A/G Plus-Agarose beads 
(Santa Cruz), washed for 3 times with TBST, resolved 
on 10% SDS gel, and detected with anti-HMGB1 or 
anti-STAT3-PY705 antibody, respectively.
ELISA quantitative analysis
Concentrations of HMGB1 or IL-10 in human 
plasma or conditioned medium were determined by 
HMGB1 ELISA kit (IBL International) [32] or IL-10 
ELISA kit (Cloud-Clone Corp.), respectively. IFN-γ 
secretion from CD8+ T lymphocytes was assessed by 
IFN-γ ELISA Kit (Cloud-Clone Corp) according to the 
manufacturer’s instructions [37].
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism software (version 5.03). For all experiments, at 
least 3 independent experiments were performed. Data 
are expressed as mean ± SD or median with interquartile 
range when variation was high. Significant difference 
between two groups with equal numbers was analyzed 
by two-sided Student t-tests and those with unequal 
sizes were analyzed with the Mann-Whitney U test. 
Two-way ANOVA with Bonferroni post-hoc test was 
used to compare difference between two groups of 
data. Correlation between two groups of variables was 
analyzed with Pearson’s correlation. All P-values < 0.05 
were considered as statistically significant. *, **, and *** 
indicate P value < 0.05, 0.001, and 0.0001, respectively.
DISCUSSION
There is accumulating evidence for the hypothesis 
that long-term clinical success of anticancer therapy 
requires the participation of immune responses to ‘danger’ 
signals emitted by cancer cells [42, 43]. Dysregulated 
immune response confers a worse clinical outcome in 
DLBCL patients treated with R-CHOP [44, 45]. Our 
present data demonstrate for the first time that rituximab 
induces a cell death-independent HMGB1 release which 
in turn elicits cytotoxic immune responses. We therefore 
propose that rituximab may eliminate malignant B-cells 
via inducing immune responses rather than a direct killing.
Treatment with R-CHOP greatly improves overall 
survival rates in patients with DLBCL compared with 
CHOP. However, our in vitro experiments showed that 
treatment with R-CHOP does not kill more DLBCL 
B-cells compared with treating with CHOP alone. 
Rituximab did not directly induce cell death as tested in 
four different DLBCL cell lines. We hypothesized that 
rituximab may kill malignant B-cells indirectly and this 
led us to determine whether rituximab elicits ICD markers 
on malignant B-cells.
We found that rituximab induced HMGB1 release 
from intact DLBCL cells. Conversely, treatment with 
CHOP induced cell death but not HMGB1 release. 
According to the concept of ICD, HMGB1 is released 
from dying or dead cells and it is a late event of ICD [18]. 
Our previous study showed that plasma from chronic 
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lymphocytic leukemia (CLL) patients has elevated 
levels of HMGB1 and the concentration of HMGB1 is 
positively correlated with the absolute lymphocyte count, 
suggesting that the plasma HMGB1 is released from live 
CLL B-cells [32]. However, this is not a phenomenon of 
malignant B-cells, because other live tumor cells, such as 
colon, gastric and liver cancer cells are also able to secret 
HMGB1 [46]. Treatment with R-CHOP increased plasma 
HMGB1 concentration in patients with DLBCL. Two of 
CHOP’s components, doxorubicin and cyclophosphamide, 
have been found as ICD inducers [47]. However, treatment 
with CHOP did not induce HMGB1 release, CRT exposure 
and ATP secretion. This may be caused by the drug 
combination which lowers the dose of each drug. In vitro 
experiments showed that rituximab-induced HMGB1 
release was detected as early as 1 hour and co-treatment 
with CHOP did not enhance HMGB1 release. We propose 
that rituximab-mediated HMGB1 release is unique and 
cell death-independent process compared with ICD 
inducers.
The mechanism of HMGB1 release from a cell is 
poorly understood. An early study demonstrated that 
HMGB1 secretion from monocytes is via lysosome 
exocytosis [30]. Our results showed that rituximab induces 
lysosome permeability but not lysosome exocytosis 
because HMGB1 release was not accompanied by the 
release of lysosomal enzyme cathepsin D. We believe that 
it will be a challenge to find out how HMGB1 is released 
from live cells.
STAT3 is constitutively activated in DLBCL cells 
[48]. It was reported that rituximab is able to inhibit STAT3 
activity and IL-10 secretion by a CD20 positive Burkitt’s 
lymphoma cell line, 2F7 [12]. Indeed, we confirmed 
that treatment with rituximab significantly inhibited the 
expression of both STAT3-PS727 and STAT3-PY705, and 
secretion of IL-10 in a panel of DLBCL cell lines. We 
also found that plasma IL-10 levels were significantly 
decreased in R-CHOP treated DLBCL patients. IL-10 is 
an immunosuppressive cytokine [49]. Inhibition of IL-10 
secretion may contribute, at least partly, to rituximab-
induced immune response.
As a nuclear protein, HMGB1 binds to DNA and 
some of transcriptional factors, and it is required for gene 
transcription [50, 51]. We hypothesized that the active 
STAT3 may bind to HMGB1 and stabilize its nuclear 
localization. Inhibition of STAT3 by rituximab may 
break this binding and cause HMGB1 release from the 
nucleus. Our results confirmed that rituximab-induced 
STAT3 inhibition is significantly correlated with HMGB1 
release. In contrast, stimulation of STAT3 by IL-10 
stabilized HMGB1 nuclear localization. HMGB1 shares 
same localization with active STAT3 in the nucleus but 
segregation occurs when they translocate from the nucleus 
to the cytoplasm. Using co-IP, we detected the interaction 
between HMGB1 and the active STAT3. IL-10 and 
rituximab played either positive or negative roles on this 
interaction. To consolidate this finding, a JAK2/STAT3 
inhibitor, AG490 was used to replace rituximab. As 
expected, AG490 induced both dose- and time-dependent 
HMGB1 release and this release is associated with an 
inhibition of STAT3 activity.
As rituximab neither induces cell death nor elicits 
other ICD markers, such as CRT exposure and ATP 
release, we propose that rituximab is unlikely an ICD 
inducer. Extracellular HMGB1 is known as one of the 
maturation factors for DCs [52]. Our results demonstrate 
that the conditioned medium from rituximab-treated 
DLBCL cells is able to induce maturation of DCs which in 
turn present tumor antigen to cytotoxic T cells. Rituximab 
alone could not induce maturation of DCs, suggesting that 
the immunogenic effect is not due to the activation of Fc 
receptor by rituximab.
It is currently unknown how rituximab-induced ICD 
is linked with previously proposed mechanism of ADCC. 
ICD is the killing mechanism by which DCs and T-cells 
are activated by tumor cell antigens and eventually tumor 
cells are killed by cytotoxic T-cells and phagocytic cells. 
ADCC is the natural killer cells kill antibody-primed 
tumor cells [53]. Both ICD and ADCC are immune-
mediated tumor cell killing, by different mechanisms and 
different immune cells. Rituximab-mediated ICD can kill 
DLBCL cells and may also enhance rituximab-induced 
ADCC.
In summary, this study demonstrates that rituximab 
induces a cell death-independent HMGB1 release which is 
associated with STAT3 inhibition. Increased extracellular 
HMGB1 and suppressed IL-10 secretion elicit cytotoxic 
immune response which may eliminate malignant B-cells 
indirectly. Our data provide a new understanding on the 
mechanism by which rituximab and other anti-CD20 
antibodies eliminate malignant B-cells.
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